Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan.
Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan.
Front Immunol. 2018 Oct 9;9:2320. doi: 10.3389/fimmu.2018.02320. eCollection 2018.
enterotoxin (CPE) is a common cause of food poisoning and hyperkalemia-associated death. Previously, we reported that fusion of pneumococcal surface protein A (PspA) to C-terminal fragment of CPE (C-CPE) efficiently bound mucosal epithelium so that PspA-specific immune responses could be provoked. In this study, we found that fusion of C-CPE with PspA augmented the antigenicity of C-CPE itself. These findings allowed us to hypothesize that fusion of C-CPE and another food poisoning vaccine act as a bivalent food poisoning vaccine. Therefore, we constructed an adjuvant-free bivalent vaccine against CPE and cholera toxin (CT), which is a major food poisoning in developing country, by genetically fusing CT B subunit to C-CPE. Because of the low antigenicity of C-CPE, immunization of mice with C-CPE alone did not induce C-CPE-specific immune responses. However, immunization with our vaccine induced both C-CPE- and CT-specific neutralizing antibody. The underlying mechanism of the augmented antigenicity of C-CPE included the activation of T cells by CTB. Moreover, neutralizing antibodies lasted for at least 48 weeks and the quality of the antibody was dependent on the binding activity of CTB-C-CPE to its receptors. These findings suggest that our fusion protein is a potential platform for the development of an adjuvant-free bivalent vaccine against CPE and CT.
肠毒素(CPE)是食物中毒和高钾血症相关死亡的常见原因。以前,我们曾报道过,将肺炎球菌表面蛋白 A(PspA)与 CPE 的 C 端片段(C-CPE)融合可以有效地结合黏膜上皮细胞,从而引发针对 PspA 的特异性免疫反应。在这项研究中,我们发现 C-CPE 与 PspA 的融合增强了 C-CPE 本身的抗原性。这些发现使我们假设,将 C-CPE 与另一种食物中毒疫苗融合可以作为一种双价食物中毒疫苗。因此,我们通过将霍乱毒素(CT)的 B 亚单位基因融合到 C-CPE 上,构建了一种无佐剂的 CPE 和霍乱毒素(CT)双价食物中毒疫苗。由于 C-CPE 的抗原性较低,单独免疫 C-CPE 不会诱导 C-CPE 特异性免疫反应。然而,用我们的疫苗免疫可以诱导 C-CPE 和 CT 的特异性中和抗体。C-CPE 抗原性增强的潜在机制包括 CTB 激活 T 细胞。此外,中和抗体至少持续 48 周,并且抗体的质量取决于 CTB-C-CPE 与其受体的结合活性。这些发现表明,我们的融合蛋白是开发无佐剂的 CPE 和 CT 双价疫苗的潜在平台。